Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel

Alp Aytekin, Maria Scalamogna, J. J. Coughlan, Shqipdona Lahu, Gjin Ndrepepa, Maurizio Menichelli, Katharina Mayer, Jochen Wöhrle, Isabell Bernlochner, Bernhard Witzenbichler, Willibald Hochholzer, Dirk Sibbing, Dominick J. Angiolillo, Rayyan Hemetsberger, Ralph Tölg, Christian Valina, Arne Müller, Sebastian Kufner, Christoph Liebetrau, Erion Xhepa, Alexander Hapfelmeier, Hendrik B. Sager, Michael Joner, Gert Richardt, Karl-Ludwig Laugwitz, Franz Josef Neumann, Heribert Schunkert, Stefanie Schüpke, Adnan Kastrati, Salvatore Cassese

Clinical Research in Cardiology（2024）

Cited 0|Views17

No score

Abstract

The ISAR-REACT 5 trial compared the efficacy and safety of ticagrelor and prasugrel in patients with ACS managed invasively. The present study sought to investigate the impact of ticagrelor and prasugrel on the incidence and pattern of urgent revascularization in acute coronary syndromes (ACS) patients undergoing percutaneous coronary intervention (PCI). This post-hoc analysis of the ISAR-REACT 5 trial included all ACS patients who underwent PCI. The primary endpoint for this analysis was the incidence of urgent revascularization at 12-month follow-up. Secondary outcome was the pattern of urgent revascularization procedures (namely, urgent target vessel/non-target vessel revascularization – TVR/NTVR). Among 3,377 ACS patients who underwent PCI, 1,676 were assigned to ticagrelor and 1,701 to prasugrel before PCI. After 12 months, the incidence of urgent revascularization was higher among patients assigned to ticagrelor as compared to prasugrel (6.8

Translated text

Key words

Antiplatelet therapy,Drug-eluting stent,Urgent revascularization,Percutaneous coronary intervention

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined